The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer

References

• Smaletz O, Scher HI, Small EJ, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002; 20: 3972–82
   PubMed Web of Science ®Google Scholar
• Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458–68
   PubMed Web of Science ®Google Scholar
• Coxon JP, Oades GM, Kirby RS, Colston KW. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int 2004; 94: 164–70
   PubMed Web of Science ®Google Scholar
• Senaratne SG, Mansi JL, Colston KW. The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. Br J Cancer 2002; 86: 1479–86
   PubMed Web of Science ®Google Scholar
• Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 1999; 17: 1654–63
   PubMed Web of Science ®Google Scholar
• Riou J. Cellular uptake and efflux of docetaxel (Taxotere) and paclitaxel (Taxol) in P388 cell line. Proc Am Assoc Cancer Res 1994; 35: 385
   Google Scholar
• Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997; 57: 229–33
   PubMed Web of Science ®Google Scholar
• Wang Q, Wieder R. All-trans retinoic acid potentiates Taxotere-induced cell death mediated by Jun N-terminal kinase in breast cancer cells. Oncogene 2004; 23: 426–33
   PubMed Web of Science ®Google Scholar
• Muenchen HJ, Poncza PJ, Pienta KJ. Different docetaxel-induced apoptotic pathways are present in prostate cancer cell lines LNCaP and PC-3. Urology 2001; 57: 366–70
   PubMed Web of Science ®Google Scholar
• Bertelli G, Heouaine A, Arena G, et al. Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients. Cancer Chemother Pharmacol 2005; 57: 46–51
   PubMed Web of Science ®Google Scholar
• Sato M, Grasser W, Endo N, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991; 88: 2095–105
   PubMed Web of Science ®Google Scholar
• Suzuki A, Kawabata T, Kato M. Necessity of interleukin-1beta converting enzyme cascade in taxotere-initiated death signaling. Eur J Pharmacol 1998; 343: 87–92
   PubMed Web of Science ®Google Scholar
• Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel. Br J Cancer 2001; 84: 1126–34
   PubMed Web of Science ®Google Scholar
• Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol 2003; 170: 246–52
   PubMed Web of Science ®Google Scholar
• Dumon, JC, Journe, F, Kheddoumi, N, Lagneaux, L, Body, JJ. Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells. Eur Urol 2004;45:521–8; Discussion 8–9.
   PubMed Web of Science ®Google Scholar
• Nogawa M, Yuasa T, Kimura S, et al. Zoledronic acid mediates Ras-independent growth inhibition of prostate cancer cells. Oncol Res 2005; 15: 1–9
   PubMed Web of Science ®Google Scholar
• Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 2005; 113: 364–71
   PubMed Web of Science ®Google Scholar
• Gomez-Lechon MJ, O'Connor E, Castell JV, Jover R. Sensitive markers used to identify compounds that trigger apoptosis in cultured hepatocytes. Toxicol Sci 2002; 65: 299–308
   PubMed Web of Science ®Google Scholar
• Tantivejkul K, Loberg RD, Mawocha SC, et al. PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism. J Cell Biochem 2005; 96: 641–52
   PubMed Web of Science ®Google Scholar
• Ullen A, Lennartsson L, Harmenberg U, et al. Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol 2005; 44: 644–50
   PubMed Web of Science ®Google Scholar
• Reyes-Moreno C, Sourla A, Choki I, Doillon C, Koutsilieris M. Osteoblast-derived survival factors protect PC-3 human prostate cancer cells from adriamycin apoptosis. Urology 1998; 52: 341–7
   PubMed Web of Science ®Google Scholar
• Tenta R, Tiblalexi D, Sotiriou E, Lembessis P, Manoussakis M, Koutsilieris M. Bone microenvironment-related growth factors modulate differentially the anticancer actions of zoledronic acid and doxorubicin on PC-3 prostate cancer cells. Prostate 2004; 59: 120–31
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Kimura S, Segawa H, et al. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 2005; 47: 31–9
   PubMed Web of Science ®Google Scholar
• Padmanabhan V, Callas P, Philips G, Trainer TD, Beatty BG. DNA replication regulation protein Mcm7 as a marker of proliferation in prostate cancer. J Clin Pathol 2004; 57: 1057–62
   PubMed Web of Science ®Google Scholar
• Meng MV, Grossfeld GD, Williams GH, et al. Minichromosome maintenance protein 2 expression in prostate: Characterization and association with outcome after therapy for cancer. Clin Cancer Res 2001; 7: 2712–8
   PubMed Web of Science ®Google Scholar